clinical trial · NCT03742037
Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus
Viatris Innovation GmbH·phase2·completed·n = 427
Systemic Lupus ErythematosusCenerimod 0.5 mgCenerimod 1 mgCenerimod 2 mgCenerimod 4 mgPlacebocenerimod 2 mg (ex-4 mg)
brief summary
The purpose of the study is to assess the efficacy and safety of 4 doses of cenerimod versus placebo in adult subjects with systemic lupus erythematosus (SLE).
started
Dec 21, 2018
primary completion
Aug 31, 2021
completion
Aug 25, 2022
last updated
Oct 3, 2025
detailed description
This is a Phase 2b, multicenter, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 4 doses of cenerimod versus placebo in adult subjects with moderately to severely active, autoantibody-positive systemic lupus erythematosus (SLE).
official title
A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Cenerimod in Subjects With Moderate to Severe Systemic Lupus Erythematosus (SLE)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol